Significance of NT-proBNP and High-sensitivity Troponin in Friedreich Ataxia

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jun 3

PMID 32481586

Citations 5

Authors

Lise Legrand

Carole Maupain

Marie-Lorraine Monin

Claire Ewenczyk

Richard Isnard

Rana Alkouri

Alexandra Durr

Francoise Pousset

Affiliations

Soon will be listed here.

Abstract

Background: Friedreich's ataxia (FA) is a rare autosomal recessive mitochondrial disease resulting of a triplet repeat expansion guanine-adenine-adenine (GAA) in the frataxin (FXN) gene, exhibiting progressive cerebellar ataxia, diabetes and cardiomyopathy. We aimed to determine the relationship between cardiac biomarkers, serum N-terminal pro-brain natriuretic peptide (NT-proBNP), and serum cardiac high-sensitivity troponin (hsTnT) concentrations, and the extent of genetic abnormality and cardiac parameters.

Methods: Between 2013 and 2015, 85 consecutive genetically confirmed FA adult patients were prospectively evaluated by measuring plasma hsTnT and NT-proBNP concentrations, electrocardiogram, and echocardiography.

Results: The 85 FA patients (49% women) with a mean age of 39 ± 12 years, a mean disease onset of 17 ± 11 years had a mean SARA (Scale for the Assessment and Rating of Ataxia) score of 26 ± 10. The median hsTnT concentration was 10 ng/L (3 to 85 ng/L) and 34% had a significant elevated hsTnT ≥ 14 ng/L. Increased septal wall thickness was associated with increased hsTnT plasma levels ( < 0.001). The median NT-proBNP concentration was 31 ng/L (5 to 775 ng/L) and 14% had significant elevated NT-proBNP ≥ 125 ng/L. Markers of increased left ventricular filling pressure (trans mitral E/A and lateral E/E' ratio) were associated with increased NT-proBNP plasma levels ( = 0.01 and = 0.01). Length of GAA or the SARA score were not associated with hsTnT or NT-proBNP plasma levels.

Conclusion: hsTnT was increased in 1/3 of the adult FA and associated with increased septal wall thickness. Increased NT-proBNP remained a marker of increased left ventricular filling pressure. This could be used to identify patients that should undergo a closer cardiac surveillance.

Citing Articles

Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort.

Shen M, Rummey C, Lynch D Ann Clin Transl Neurol. 2024; 11(5):1110-1121.

PMID: 38396238 PMC: 11093247. DOI: 10.1002/acn3.52027.

Cardiovascular Research in Friedreich Ataxia: Unmet Needs and Opportunities.

Payne R JACC Basic Transl Sci. 2023; 7(12):1267-1283.

PMID: 36644283 PMC: 9831864. DOI: 10.1016/j.jacbts.2022.04.005.

Friedreich ataxia: clinical features and new developments.

Keita M, McIntyre K, Rodden L, Schadt K, Lynch D Neurodegener Dis Manag. 2022; 12(5):267-283.

PMID: 35766110 PMC: 9517959. DOI: 10.2217/nmt-2022-0011.

Downregulation of Three Immune-Specific Core Genes and the Regulatory Pathways in Children and Adult Friedreich's Ataxia: A Comprehensive Analysis Based on Microarray.

Liu L, Lai Y, Zhan Z, Fu Q, Jiang Y Front Neurol. 2022; 12:816393.

PMID: 35237223 PMC: 8884172. DOI: 10.3389/fneur.2021.816393.

The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia.

Frempong B, Wilson R, Schadt K, Lynch D Front Neurosci. 2021; 15:653241.

PMID: 33737864 PMC: 7960909. DOI: 10.3389/fnins.2021.653241.

References

Koeppen A . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011; 303(1-2):1-12. PMC: 3062632. DOI: 10.1016/j.jns.2011.01.010. View

Jenab Y, Pourjafari M, Darabi F, Boroumand M, Zoroufian A, Jalali A . Prevalence and determinants of elevated high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Cardiol. 2013; 63(2):140-4. DOI: 10.1016/j.jjcc.2013.07.008. View

Rivas-Gotz C, Manolios M, Thohan V, Nagueh S . Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol. 2003; 91(6):780-4. DOI: 10.1016/s0002-9149(02)03433-1. View

Reetz K, Dogan I, Costa A, Dafotakis M, Fedosov K, Giunti P . Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015; 14(2):174-82. DOI: 10.1016/S1474-4422(14)70321-7. View

Reetz K, Dogan I, Hilgers R, Giunti P, Mariotti C, Durr A . Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016; 15(13):1346-1354. DOI: 10.1016/S1474-4422(16)30287-3. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

Foppa M, Duncan B, Rohde L . Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?. Cardiovasc Ultrasound. 2005; 3:17. PMC: 1183230. DOI: 10.1186/1476-7120-3-17. View

Campuzano V, Montermini L, Molto M, Pianese L, Cossee M, Cavalcanti F . Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996; 271(5254):1423-7. DOI: 10.1126/science.271.5254.1423. View

Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C . Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996; 335(16):1169-75. DOI: 10.1056/NEJM199610173351601. View

10.

Weidemann F, Liu D, Hu K, Florescu C, Niemann M, Herrmann S . The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvement. Int J Cardiol. 2015; 194:50-7. DOI: 10.1016/j.ijcard.2015.05.074. View

11.

Coats C, Parisi V, Ramos M, Janagarajan K, OMahony C, Dawnay A . Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol. 2012; 111(1):111-7. DOI: 10.1016/j.amjcard.2012.08.055. View

12.

Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T . Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart. 2003; 89(6):659-60. PMC: 1767695. DOI: 10.1136/heart.89.6.659. View

13.

Marelli C, Figoni J, Charles P, Anheim M, Tchikviladze M, Vincitorio C . Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity. Mov Disord. 2011; 27(1):135-8. DOI: 10.1002/mds.23879. View

14.

Friedman L, Schadt K, Regner S, Mark G, Lin K, Sciascia T . Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia. Int J Cardiol. 2012; 167(4):1622-4. DOI: 10.1016/j.ijcard.2012.04.159. View

15.

Tsou A, Paulsen E, Lagedrost S, Perlman S, Mathews K, Wilmot G . Mortality in Friedreich ataxia. J Neurol Sci. 2011; 307(1-2):46-9. DOI: 10.1016/j.jns.2011.05.023. View

16.

Koeppen A, Ramirez R, Becker A, Bjork S, Levi S, Santambrogio P . The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One. 2015; 10(3):e0116396. PMC: 4349588. DOI: 10.1371/journal.pone.0116396. View

17.

Pousset F, Legrand L, Monin M, Ewenczyk C, Charles P, Komajda M . A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. JAMA Neurol. 2015; 72(11):1334-41. DOI: 10.1001/jamaneurol.2015.1855. View

18.

Henry W, Gardin J, Ware J . Echocardiographic measurements in normal subjects from infancy to old age. Circulation. 1980; 62(5):1054-61. DOI: 10.1161/01.cir.62.5.1054. View

19.

Coats C, Gallagher M, Foley M, OMahony C, Critoph C, Gimeno J . Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013; 34(32):2529-37. DOI: 10.1093/eurheartj/eht070. View

20.

Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K . Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 62(14):1252-1259. DOI: 10.1016/j.jacc.2013.03.055. View